Scaling up ART treatment capacity: lessons learned from South Africa, Zimbabwe, and Botswana.

Curr Infect Dis Rep

Division of AIDS, Harvard Medical School, 401 Park Drive, Second Floor East, Boston, MA 02171, USA.

Published: March 2008

Over the past 3 years, significant strides have been made in the effort to provide antiretroviral therapy (ART) to the millions of people worldwide who require treatment for HIV. In 2006, 1.3 million people had initiated ART in sub-Saharan Africa, which is a 10-fold increase over the number who had access to treatment 3 years prior. Though this progress should be acknowledged, achieving universal access will require much more work. As countries initiate large-scale treatment programs, many political, social, economic, and operational challenges have become evident. South Africa, Zimbabwe, and Botswana are three neighboring countries engaged in ART roll-out. This paper describes the HIV epidemic in these three countries, details the most critical challenges inhibiting the progression of antiretroviral therapy roll-out, and highlights successes within each setting.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11908-008-0012-0DOI Listing

Publication Analysis

Top Keywords

south africa
8
africa zimbabwe
8
zimbabwe botswana
8
antiretroviral therapy
8
scaling art
4
treatment
4
art treatment
4
treatment capacity
4
capacity lessons
4
lessons learned
4

Similar Publications

High Detection Rate of Rotavirus Infection Among Children Admitted with Acute Gastroenteritis to Six Public Hospitals in Luanda Province After the Introduction of Rotarix Vaccine: A Cross-Sectional Study.

Viruses

December 2024

Associate Laboratory for Animal and Veterinary Sciences (AL4AnimalS), Interdisciplinary Center for Research in Animal Health (CIISA), Faculty of Veterinary Medicine, University of Lisbon, 1300-477 Lisbon, Portugal.

Rotavirus group A (RVA) is a major cause of pediatric acute gastroenteritis (AGE). Vaccination is an effective public health strategy and Angola implemented it in 2014. This hospital-based study aimed to estimate the prevalence of RVA infection and the severity of AGE in children under five years of age treated at six hospitals in Luanda Province.

View Article and Find Full Text PDF

Setting up a global SARS-CoV-2 surveillance system requires an understanding of how virus isolation and propagation practices, use of animal or human sera, and different neutralisation assay platforms influence assessment of SARS-CoV-2 antigenicity. In this study, with the contribution of 15 independent laboratories across all WHO regions, we carried out a controlled analysis of neutralisation assay platforms using the first WHO International Standard for antibodies to SARS-CoV-2 variants of concern (source: NIBSC). Live virus isolates (source: WHO BioHub or individual labs) or spike plasmids (individual labs) for pseudovirus production were used to perform neutralisation assays using the same serum panels.

View Article and Find Full Text PDF

Access to safe water and food is a critical issue in sub-Saharan Africa, where microbial contamination poses significant health risks. Conventional water treatment and food preservation methods have limitations in addressing water safety, particularly for antibiotic-resistant bacteria and other pathogenic microorganisms. This review explores the potential application of bacteriophages as an innovative solution for water treatment and food safety in the region.

View Article and Find Full Text PDF

This systematic review and meta-analysis evaluate human papillomavirus (HPV) prevalence, genotype distribution, and associations with cervicovaginal microbiota and cytokine profiles among South African women, where cervical cancer ranks as the second most common cancer. PubMed, SCOPUS, and Web of Science were searched for studies on HPV infection up to 21 September 2024. The pooled prevalence was estimated using a random-effects model, with subgroup analyses by province, sample type, and HIV status.

View Article and Find Full Text PDF

Islatravir (ISL) is the first-in-class nucleoside reverse transcriptase translocation inhibitor (NRTtI) with novel modes of action. Data on ISL resistance are currently limited, particularly to HIV-1 non-B subtypes. This study aimed to assess prevalent nucleos(t)ide reverse transcriptase inhibitor (NRTI)-resistant mutations in HIV-1 subtype C for their phenotypic resistance to ISL.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!